Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
- 23.7 mg (3 capsules of 7.9 mg) orally twice daily (approximately 12 hours apart).
- Avoid use if baseline eGFR ≤45 mL/min/1.73 m² unless benefit outweighs risk.
- If eGFR drops to 30–44 mL/min/1.73 m² during treatment: reduce dose to 15.8 mg (2 capsules) BID; if no improvement within 4 weeks, discontinue.
- If eGFR drops to <30 mL/min/1.73 m²: discontinue voclosporin.
- For severe renal impairment at baseline (eGFR 15–29 mL/min/1.73 m²): starting dose of 15.8 mg BID if used; discontinuation rules apply as above.
- On empty stomach (1 hour before or 2 hours after a meal).
- In combination with mycophenolate mofetil (MMF) and rapidly tapered corticosteroids.